It is not easy to define cancer malnutrition. Biochemical, anthropometric and immunologic parameters are used for the diagnosis. The most important biochemical test to diagnose malnutrition is serum albumin levels, and to monitor nutritional status changes levels of proteins with shorter half-lives (prealbumin and transferrin). Among anthropometric tests, the unintended weight loss of >10% of the predicted value during the preceding 3 months is a very good index. Other parameters are: arm circumference (normal range: men >23 cm, women >22 cm) indicating the muscle tissue mass and skin fold thickness over the triceps muscle (normal range: men >10 mm, women >13 mm), an indicator of fat reserves, and the determination of total intracellular potassium using the K42
ORIGINAL ARTICLE
Effects of megestrol acetate in patients with cancer anorexia-cachexia syndromea systematic review and meta-analysis The following key words were employed for the search strategy: neoplasm, cancer, cachexia, anorexia, megestrol acetate. There were no language restrictions on publications. Conference abstracts were also analyzed.
isotope, which enables body cell mass assessment. Considering immunological parameters the lymphocyte count (decreased in malnutrition) is most commonly used in practice.
3 In the diagnostic process these above mentioned criteria for ACS are often neglected, which is one of the factors responsible for MA abuse in Poland.
The MA is commonly used in Poland, which is also reflected through its high rank on the list of reimbursed expenses. For ACS in the course of cancer treatment, the form of a suspension and for hormone-dependent cancer the tablets are being reimbursed.
PATIENTs AND mEThODs The aim of this systematic review with a meta-analysis was the as- In the studies in which MA was compared with other drugs or a placebo, the doses of MA ranged from 160 mg/d 8 -12 Two studies with a short duration of drug administration (up to 10 days) were performed as cross-over trials 6, 27 , the remaining trials were parallel trials.
The majority of studies were performed with the use of placebo, or with blinding of the alternative intervention in the control group; with the exception of the Giacos et al. study 28 (lack of placebo, lack of blinding) and the Loprinzi et al.
29
(MA vs dexamethasone vs fluoxymesterone).
The methodological quality of studies included in the analysis: 1 the majority of the studies were placebo controlled and blinded 2 the randomization process has not been described in most cases 3 patients who died within the follow-up period were excluded from the analysis in several studies; in the majority of studies the analysis did not include a large number of patients (30-40%), mainly because of their withdrawal 4 in the present analysis, the proportion of patients in whom a certain outcome occurred was calculated, as far as possible, in relation to the number of patients randomized (intention-to-treat analysis); in some original studies the per-protocol analysis was used in which only patients who completed the study were included 5 in several studies the authors did not show the numerical data regarding some predefined outcomes, or presented data were incomplete, which made it impossible to use them in the present meta-analysis; publication bias may be suspected, which lowers the validity of this meta-analysis 6 despite the methodological limitations, studies included in the analysis represent the best available evidence on the effects of MA use in ACS associated with advanced cancer.
meta-analysis
The estimated effect size for various outcomes is shown in Identified studies have been initially assessed and selected on the basis of their eligibility for the reviewed topic. Then the validity of selected studies was assessed considering randomization, the intention to treat analysis and the completeness of follow-up. 5 The following persons were responsible for defining the clinical question, outcome selection, and assessment of clinical aspects of results: Roman Jaeschke, Maciej Krzakowski and Wiktoria Leśniak.
Available evidence review, methodology assessment, data identification, and their entering into the Review Manager was done independently by 2 persons (Wiktoria Leśniak and Małgorzata Bała or Roman Jaeschke).
statistical analysis The results of primary studies were pooled by meta-analysis using the DerSimonian and Laird method, employing the Review Manager 4.2.10 program. The statistical significance of overall effects was calculated with the use of the Z test, and the homogeneity of results between studies was assessed with the χ 2 and I 2 tests.
The results were summarized using the method developed by the GRADE group, which works on the grading of recommendations in clinical practice guidelines.
REsULTs Description of included studies Thirty studies have been included in the review, 5 of which were conference abstracts. The studies' description (population description, drugs compared and their doses, the number of participants, study duration) are shown in TAbLE 1 (available in the electronic version of the article). All studies included advanced stage cancer patients with the exclusion of hormone-dependent cancer; most of the studies included patients suffering from various cancers, in several studies lung cancer was the inclusion criterion, in several others head and neck cancer.
The shortest duration of follow-up was 1 week 6 , the longest 2 years 7 ; in the remaining studies the median or mean follow-up period ranged from 2 to 24 weeks. ). 6 In studies with available data, the probability of the one-year survival was less than 25%. In several studies 7, 8, 29, 30, 35 survival was assessed and no differences were demonstrated between those using MA and placebo or glucocorticosteroids 29 . The numerical data regarding MA influence on the one-year survival in comparison with placebo, was reported in 2 studies (TAbLE 2) 7, 35 . 7 The appetite improving and weight increasing effect of MA was noticeable after a few weeks of its administration. showed similar results: a beneficial trend towards weight gain with a higher dose (RR 0.77, 95% CI 0.55-1.09) and lack of the effect on appetite (outcome assessed only in 1 study 25 ). 9 An assessment of the quality of data on the effects of MA administration in ACS and a summary of the results are shown in TAbLE 2 according to the GRADE system. 36 10 The diversity of studies included in the meta-analysis, regarding study populations and interventions, does not allow the isolation of patients with the greatest chance of benefiting from MA treatment.
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5 C fluoxymesterone 29 was associated with a beneficial trend toward MA regarding the rate of patients with appetite improvement and weight gain. 4 Comparing MA with z glucocorticoster
DIsCUssION
The presented systematic review and the attempt at summarizing quantitatively the results did not bring unexpected conclusions. Similarly to the previously published meta-analyses 4,37,38 , an appetite improvement shown in absolute values (number needed to treat [NNT] c. 3-4) and weight gain (NNT c. 8) can be noticed. In the previously published meta-analyses comparable results regarding weight gain (RB 2.16, 95% CI 1.45-3.21 and relative benefit [RB] 2.14, 95% CI 1.41-3. 24) 4,38 and appetite improvement (RB 2.33; 95% CI 1.52-3.59 and RB 3.03; 95% CI 1.83-5.01) were obtained 4,38 . For appetite improvement, a difference in favor of MA, shown in the present publication and in the Berenstein and Ortiz review, results from the inclusion of an additional study.
32
C resulted in appetite improvement in a greater percentage of patients (TAbLE 2) 11, 16, 25, 30, 32 ; lack of homogeneity of results for this comparison has been demonstrated (FIGURE 2) D in studies in which a 100-milimeter visual scale was used for appetite assessment 6,27,28 the mean difference between groups was 14 mm (95% CI 7-21); a difference of this range for a certain patient is regarded as a clinically significant one, when measuring symptoms and the quality of life. In the meta-analysis of all available studies with an assessment of appetite change from baseline values 6,9,27,28 , standardized mean difference (SMD) expressed in standard deviation (SD) units was 0.44 (95% CI 0.20-0.68), which corresponds to medium effect size in the whole group of patients. It may also correspond to e.g. a large effect size of treatment in every other patient E was associated with a trend toward a lower risk of patients' performance status worsening (according to the Karnofsky or ECOG scales) 12 The inclusion of this study also caused lack of result homogeneity, though the results of individual studies indicated at least a trend of beneficial effect of MA. The absolute benefit increase in appetite improvement in the previous meta-analysis 4 was c. 27%, which corresponded to the NNT of c. 4. In the Lopez et al. publication 4 , the relative benefit of Karnofsky performance status improvement with MA administration, in comparison with the probability of improvement with the placebo administration, was 1.64 (95% CI 1.06-2.55).
To obtain appetite improvement, a low dose (160 mg) seems to be as efficient as higher doses; in the case of weight gain there is probably dose-response relationship.
The conclusions regarding MA influence on other symptoms occurrence, quality of life indexes, overall well-being and the performance status are less obvious and less convincing (scarce evidence, probability of publication bias), however studies with available data seem to indicate superiority of the drug. The influence of MA on survival in comparison with placebo could be assessed only in 2 studies (TAbLE 2) .
One of the potential interpretations of the evidence is that MA administration is associated with appetite improvement, an increased probability of weight gain and with a greater probability of delaying the performance status deterioration (the assessment of the latter effect is less certain).
Available data shows no difference between MA and glucocorticosteroids.
In the present publication the effects of drug administration have been shown with the use of relative (RR, RB) and absolute (absolute benefit increase [ABI], NNT) values, which enables to assess the balance between beneficial and harmful aspects of the drug effect and its costs. As such assessments are by their nature subjective (i.e. it may be estimated that with MA the weight increases additionally in only 10--15% of patients or in as much as 10-15% of patients), clinical decisions may also reflect subjective circumstances, for example, the significance attributed by patients and their families to the emotional and symbolic aspects of food intake and absorption.
Implications for clinical practice 1 The influence of MA on the survival rate in the advanced cancer patients has not been demonstrated. 2 In the majority of patients weight loss progresses independently of treatment, and the drug administration is associated with at least short-term weight gain in additional 10-15% of patients. 3 Although a decrease in appetite or its loss persist in most individuals, the drug administration improves this aspect of the quality of life in c. 30% of patients. 4 Compared with placebo, MA induces weight gain and appetite improvement. In a single study an overall improvement of well-being has been 7 Two studies, inverse results. Small study with a trend to the advantage of MA, large study with a trend to the advantage of GKS. Statistical analysis with a trend to MA, however more patients with improvement on GKS. 8 Lowest tested dose.
including appetite improvement and weight gain.
Because of a low value of available studies, for a more reliable assessment of MA efficacy in cancer-associated ACS it is necessary to perform a randomized controlled tral of high methodological quality.
demonstrated, the assessment of other quality of life aspects did not lead to practical implications. Beneficial effects on body weight increased with the dose. However, even the lowest daily dose (160 mg) showed a beneficial trend compared to placebo. A statistically significant influence of a dose increase on appetite improvement has not been demonstrated. 5 A comparison of the effects of MA and glucocorticosteroid administration did not show difference in appetite improvement and weight gain. 6 Lower extremity edema in short-term follow-up, and probably the thromboembolic complications risk increase in long-term follow-up are the adverse effects of MA demonstrated in previous publications 4 .
Implications for further studies Further determination of the MA role in ACS syndrome treatment requires determining the relative value (utility) attributed by patients to individual health conditions associated with the drug administration, 
